|
|
| ¡®¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 84 | 5 |  | 2.98 |
| halal haccp | 4 | | 2.38 |
| ·íÒÇÑ´àªéÒ-àÂç¹ | 4 | | 2.38 |
| ª×èͺÃÔÉÑ·¼Ùé¼ÅÔµ¼ÅäÁéáÅÐÍÒËÒúÃÃ¨Ø ·Ø¡¨Ñ§ËÇÑ´ | 4 | | 2.38 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 84 | 4 | | 2.38 |
| ÁÍ¡.152-2539 à¤Ã×èͧÊÓÍÒ§ : ¢éÍ¡Ó˹´·ÑèÇä» = cosmetics : general specification. | 3 | | 1.79 |
| »ÃСÒÈ ¨ÕàÍçÁ¾Õ 54 »ÃÐàÀ· | 3 | | 1.79 |
| ÇÔ·ÂÒ¹Ô¾¹¸ì ¤Ñ´àÅ×͡Ấ·ÕàÃÕ | 2 | | 1.19 |
| lexitron.vbs | 2 | | 1.19 |
| ¡Í§¤Çº¤ØÁÂÒ ÊÓ ¹Ñ¡§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 2 | | 1.19 |
| »Ñ¨¨Ñ·ÕèÁռŵèÍ¡ÒõѴÊÔ¹ã¨àÅ×Í¡ãªéºÃÔ¡ÒáӨѡáÁŧ | 2 | | 1.19 |
| spontaneous report of adverse drug reaction | 2 | | 1.19 |
| e-book ÊÒûÃاáµè§ÍÒËÒõèÒ§æ | 2 | | 1.19 |
| Í.ÃÐÊÒ¹¹·ì | 2 | | 1.19 |
| à·¤¹Ô¤¡ÒûÃÒȨҡàª×éÍ | 2 | | 1.19 |
| ÇԨѠà¤Ã×èͧÊÓÍÒ§ | 2 | | 1.19 |
| Áҵðҹ ¹éÓ ´×èÁ ºÃÃ¨Ø ¢Ç´ | 2 | | 1.19 |
| food and drug | 2 | | 1.19 |
| ¤ÙèÁ×Í gmp | 2 | | 1.19 |
| ÊÃØ»¡ÒÃÊÒ¸ÒóÊØ¢ä·Â2548-2550 | 2 | | 1.19 |
| ÃÐàºÕº¡ÒÃ¢Í Í. | 2 | | 1.19 |
| à·ÍÃìâÁÁÔàµÍÃìÇÑ´ä¢é | 2 | | 1.19 |
| spontaneous report | 2 | | 1.19 |
| ¢éÍÁÙÅ gmp | 2 | | 1.19 |
| p-phenylenediamine | 2 | | 1.19 |
| ÊÒ¸ÒóÊØ¢ªØÁª¹ ¼Ñ§âç§Ò¹à¤Ã×èͧÊÓÍÒ§ | 2 | | 1.19 |
| ÇÔÃѪ ªÔ¹ÇÔ¹Ô¨¡ØÅ | 1 | | 0.60 |
| ˹ѧÊ×Íࡳ±ì¡ÒþԨÒóҡÒâÖé¹·ÐàºÕ¹µÓÃѺÍÒËÒÃáÅСÒÃ͹ØÒµ¹éÓÁѹáÅÐä¢Áѹ | 1 | | 0.60 |
| muti-strain epidemic model | 1 | | 0.60 |
| ÊÑ觫×éÍ ÂÒÊź | 1 | | 0.60 |
| à¾Å§ÎÔµ | 1 | | 0.60 |
| ¼Å¡Ãзº¨Ò¡ÊÒÃàʾµÔ´¨Ð·ÓãËé¤ÇÒÁµéÒ¹·Ò¹âä¹éÍ | 1 | | 0.60 |
| ÂÒerlotinib | 1 | | 0.60 |
| »ÃÐÁÇÅÃÒª×èÍáÅÐÃËÑÊà¤Ã×èͧÁ×Íá¾·Âì | 1 | | 0.60 |
| àµÕ§ ¹Ç´ ä¿¿éÒ | 1 | | 0.60 |
| webdb.dmsc.moph.go.th/ifc_toxic/a_tx_1_001c.a... | 1 | | 0.60 |
| «è͹ mycomputer | 1 | | 0.60 |
| atheromatous | 1 | | 0.60 |
| ¡ÒèѴ·Ó haccp¡ÒüÅÔµ¡Øé§ | 1 | | 0.60 |
| ¾ÃÐÃÒªºÑÑµÔ ÂÒ àʾ µÔ´ ãËé â·É ¾ È 2545 | 1 | | 0.60 |
| ÊÑè§Âҹ͹ËÅѺ | 1 | | 0.60 |
| ¡ÒþѲ¹ÒËéͧÊÁØ´ iso 9001 | 1 | | 0.60 |
| ¡®¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè61 | 1 | | 0.60 |
| anti-nausea medicine | 1 | | 0.60 |
| âçàÃÕ¹ÇÑ´ÂÒÂÃèÁ | 1 | | 0.60 |
| ÈÙ¹ÂìºÃÔ¡ÒÃÊÒ¸ÒóÊØ¢ 51 ÇÑ´ä¼èµÑ¹ àÇÅÒ·Ó¡Òà | 1 | | 0.60 |
| ¢éÍ¡Ó˹´ÊÕ¤ÒÃÒàÁÅ ¡®¡ÃзÃǧ | 1 | | 0.60 |
| ¡ÒèѴ¡Ò÷ÃѾÂÒ¡ÃÁ¹ØÉÂì´éÇ competency based hrm | 1 | | 0.60 |
| à¤Ã×èͧà¾ÒжÑèǧ͡ | 1 | | 0.60 |
| ÇÔ¸Õãªé¢Õé¼Ö駻éÒÂµÒ | 1 | | 0.60 |
| ¡®¡ÃзÃǧÊÒ¸ÒóÊØ¢·Õèà¡ÕèÂǡѺÊÕ¼ÊÁÍÒËÒà | 1 | | 0.60 |
| Çѵ¶Øà¨×Í»¹ÍÒËÒà »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 84; 2527: 25. | 1 | | 0.60 |
| Êèǹ»ÃСͺ¢Í§ä¢è | 1 | | 0.60 |
| Êӹѡ§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 1 | | 0.60 |
| aspirinÂÒÊÃþ¤Ø³ | 1 | | 0.60 |
| àÅ«ÔµÔ¹ ¾Ñ²¹ÒÊÁͧ | 1 | | 0.60 |
| Êӹѡ§Ò¹ÍÒËÒÃáÅÐÂÒ àÅ×Í´¨ÃÐà¢é | 1 | | 0.60 |
| â¤Ã§¡Òà ͺÃÁ ¡ÒüÅÔµ¹éíÒÁѹËÍÁÃÐàË àªÕ§ãËÁè | 1 | | 0.60 |
| ÇÑ·ͧá¡éËÁѹ | 1 | | 0.60 |
| âä post-traumatic stress disorder [ptsd] | 1 | | 0.60 |
,
User's Guide
˹éÒÅçÍ¡ÍÔ¹| ʶԵÔÃÒ»Õ
| ʶԵÔÃÒÂà´×͹
| ʶԵÔÃÒÂÇѹ
| ʶԵÔÃÒªÑèÇâÁ§
| Eng
Pageview 
Unique IPs 
Sessions